Pfizer's Prevnar 13 Backed by U.S. Panel for Expanded Use - Analyst Blog

A generic image of a pen next to a pile of coins
Credit: Shutterstock photo

Prevnar 13 (a vaccine for the prevention of pneumococcal disease) is one of the most important products in Pfizer's ( PFE ) portfolio. The vaccine performed impressively in the second quarter of 2014 with sales being positively impacted by government purchasing patterns and higher demand.

Pfizer received some more encouraging news on Prevnar 13 earlier in the week with the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommending the routine use of the vaccine in patients aged 65 years and above for the prevention of pneumococcal disease including pneumonia caused by the 13 pneumococcal serotypes contained in the vaccine. The panel is in favor of the reevaluation of its above recommendation in 2018.

Specifically, the advisory panel recommended immunization by a dose of Prevnar 13, followed by a dose of Merck's ( MRK ) Pneumovax 23 in elders who have not received pneumococcal vaccine before. This recommendation is also applicable for patients whose history of vaccination is not known. The panel also recommended the use of Prevnar 13 in patients who have already received at least one dose of Merck's vaccine.

Pfizer stated in its press release that the advisory panel's recommendations will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and subsequent approval. We note that Prevnar 13 is already available for use in younger patients. Approval in patients aged 65 and above would further increase the drug's sales potential.

Pfizer is looking to strengthen its vaccines portfolio. To that end, the pharmaceutical behemoth inked a deal with Baxter International ( BAX ) last month to buy the latter's portfolio of marketed vaccines. (Read: Baxter International Falls as Pfizer Acquires Vaccines )

Pfizer carries a Zacks Rank #3 (Hold). A better-ranked large cap pharma stock is AstraZeneca ( AZN ) which holds a Zacks Rank # 2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

BAXTER INTL (BAX): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More